About gain therapeutics inc - GANX
Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never targeted before. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.
GANX At a Glance
Gain Therapeutics, Inc.
4800 Montgomery Lane
Bethesda, Maryland 20814
| Phone | 1-301-500-1556 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -20,411,191.00 | |
| Sector | Health Technology | Employees | 25 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
GANX Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 7.985 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.958 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.016 |
GANX Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -816,447.64 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
GANX Liquidity
| Current Ratio | 2.966 |
| Quick Ratio | 2.966 |
| Cash Ratio | 2.655 |
GANX Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -132.828 |
| Return on Equity | -204.954 |
| Return on Total Capital | -255.376 |
| Return on Invested Capital | -194.59 |
GANX Capital Structure
| Total Debt to Total Equity | 8.897 |
| Total Debt to Total Capital | 8.17 |
| Total Debt to Total Assets | 5.386 |
| Long-Term Debt to Equity | 5.204 |
| Long-Term Debt to Total Capital | 4.778 |